Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis
Authors' conclusion
In this large, multicenter, real world cohort study, GLP-1 RA use was associated with a significantly reduced long term risk of TKA in patients with knee OA, with effects that were greater with longer treatment duration and newer generation agents.
Study context
- Population
- Adults with knee osteoarthritis (OA) diagnosed between January 1, 2010, and December 31, 2024matched cohorts 13,351 to 42,062
- Exposure
- GLP-1 RA use vs propensity score matched non-exposed
- Outcome
- Cumulative incidence of TKA
- Follow-up
- 1, 3, 5, and 8 years
Methodological detailspropensity score matched, multicenter, TriNetX Global Research Network database
- Propensity score matched
- Multicenter
- TriNetX Global Research Network database
Main finding
As reported in the abstract
Cumulative TKA incidence · 8 years
Each group vs non-exposedHazard ratio (95% CI)
Any GLP-1 RA1 year exposure; absolute risk difference −2.80 percentage points
0.90(0.83–0.98)
New generation GLP-1 RA3 year exposure; absolute risk difference −4.71 percentage points
0.72(0.67–0.78)
- Significantly lower cumulative total knee arthroplasty (TKA) incidence across all exposure classes, durations, and follow-up intervals
- all p<0.001
Observational data: associations, not effects.
Original publication
Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis. Reg Anesth Pain Med. Published 2 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →